Research Analysts Issue Forecasts for APLS Q3 Earnings

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) – Research analysts at Wedbush raised their Q3 2025 EPS estimates for Apellis Pharmaceuticals in a note issued to investors on Tuesday, July 15th. Wedbush analyst L. Chico now forecasts that the company will post earnings of $1.41 per share for the quarter, up from their prior forecast of $1.35. The consensus estimate for Apellis Pharmaceuticals’ current full-year earnings is ($1.70) per share.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its quarterly earnings data on Wednesday, May 7th. The company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.38). The firm had revenue of $149.90 million during the quarter, compared to analyst estimates of $197.61 million. Apellis Pharmaceuticals had a negative net margin of 28.83% and a negative return on equity of 99.19%. The business’s quarterly revenue was down 3.2% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.54) EPS.

A number of other equities research analysts also recently issued reports on APLS. Bank of America boosted their target price on shares of Apellis Pharmaceuticals from $23.00 to $24.00 and gave the company a “neutral” rating in a report on Wednesday. Royal Bank Of Canada lowered their target price on shares of Apellis Pharmaceuticals from $21.00 to $18.00 and set a “sector perform” rating for the company in a report on Thursday, May 8th. Wells Fargo & Company boosted their target price on shares of Apellis Pharmaceuticals from $26.00 to $29.00 and gave the company an “equal weight” rating in a report on Monday, June 2nd. Mizuho lowered their target price on shares of Apellis Pharmaceuticals from $30.00 to $20.00 and set a “neutral” rating for the company in a report on Wednesday, May 14th. Finally, Morgan Stanley boosted their target price on shares of Apellis Pharmaceuticals from $25.00 to $26.00 and gave the company an “equal weight” rating in a report on Wednesday, July 2nd. Nine research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $39.84.

Apellis Pharmaceuticals Stock Performance

NASDAQ:APLS opened at $19.75 on Wednesday. The firm has a 50 day simple moving average of $18.14 and a 200-day simple moving average of $22.81. The company has a debt-to-equity ratio of 2.76, a current ratio of 4.08 and a quick ratio of 3.62. The firm has a market cap of $2.48 billion, a PE ratio of -11.03 and a beta of 0.67. Apellis Pharmaceuticals has a 1-year low of $16.10 and a 1-year high of $41.94.

Institutional Trading of Apellis Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in APLS. EverSource Wealth Advisors LLC raised its holdings in Apellis Pharmaceuticals by 2,707.1% in the fourth quarter. EverSource Wealth Advisors LLC now owns 786 shares of the company’s stock valued at $25,000 after acquiring an additional 758 shares in the last quarter. Assetmark Inc. raised its holdings in Apellis Pharmaceuticals by 3,938.7% in the first quarter. Assetmark Inc. now owns 1,252 shares of the company’s stock valued at $27,000 after acquiring an additional 1,221 shares in the last quarter. Parallel Advisors LLC raised its holdings in Apellis Pharmaceuticals by 80.0% in the second quarter. Parallel Advisors LLC now owns 1,924 shares of the company’s stock valued at $33,000 after acquiring an additional 855 shares in the last quarter. Signaturefd LLC raised its holdings in Apellis Pharmaceuticals by 357.2% in the fourth quarter. Signaturefd LLC now owns 1,175 shares of the company’s stock valued at $37,000 after acquiring an additional 918 shares in the last quarter. Finally, GF Fund Management CO. LTD. raised its holdings in Apellis Pharmaceuticals by 21.9% in the first quarter. GF Fund Management CO. LTD. now owns 3,185 shares of the company’s stock valued at $70,000 after acquiring an additional 573 shares in the last quarter. 96.29% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, General Counsel David O. Watson sold 5,000 shares of the company’s stock in a transaction on Monday, June 16th. The shares were sold at an average price of $18.77, for a total value of $93,850.00. Following the sale, the general counsel directly owned 133,730 shares of the company’s stock, valued at $2,510,112.10. This represents a 3.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Cedric Francois sold 137,465 shares of the company’s stock in a transaction on Monday, July 14th. The shares were sold at an average price of $20.19, for a total transaction of $2,775,418.35. Following the completion of the sale, the chief executive officer directly owned 343,433 shares in the company, valued at $6,933,912.27. This represents a 28.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 144,365 shares of company stock worth $2,907,439. Corporate insiders own 6.50% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).